• SNORA38B in NSCLC: TME Remodeling and ICB Response

  2026-10-09

  The reference study identifies SNORA38B as a snoRNA associated with NSCLC progression and links its activity to E2F1-dependent regulation of the GAB2/AKT/mTOR pathway. Its mouse-model findings suggest that suppressing SNORA38B can reshape the tumor immune microenvironment and improve response to immune checkpoint blockade, although clinical applicability remains unestablished.

• Nav1.5 Ser571 Links Cardiac Aging to Late Na⁺ Current

  2026-10-09

  A 2024 study identifies Nav1.5 Ser571 phosphorylation as a mechanistic link between increased late sodium current, delayed ventricular repolarization, and impaired diastolic function during cardiac aging. Its genetically directed design strengthens the case that late sodium current is not merely an associated phenotype but a modifiable contributor to age-related electrical and mechanical dysfunction.

• Etomoxir in Immunometabolism Research: Evidence and Limits

  2026-10-08

  Etomoxir is a useful pharmacological probe for asking how lipid metabolism may influence immune activation, but its interpretation requires caution. This overview separates findings from supplier claims, examines whole-blood and model-system applications, and explains why reported effects cannot automatically be attributed to CPT-1 inhibition or translated into therapeutic conclusions.

• TH287 and MTH1 Inhibition in Cancer Radiosensitization

  2026-10-08

  TH287 is being studied as an MTH1 inhibitor that may increase oxidative DNA damage and radiosensitivity in cancer models. Recent evidence in PC-3 and DU-145 castration-resistant prostate cancer cells supports a schedule-dependent combination effect, but the findings remain preclinical and require broader validation.

• Etomoxir and the Next Era of Immunometabolism

  2026-10-07

  Etomoxir is more than a fatty acid oxidation inhibitor: it is a pharmacological lens for examining how mitochondrial lipid use shapes immune function. This article connects CPT-1 biology with standardized whole-blood immunometabolism, highlights the interpretive importance of DGAT activity, and defines a translational framework that separates mechanistic evidence from therapeutic promise.

• VE-821: ATR Inhibition and Evidence Boundaries

  2026-10-07

  VE-821 is an ATR kinase inhibitor used in DNA damage response research. Vendor-reported potency and sensitization claims support checkpoint studies, but the 2024 HBoV1 study provides DNMT1 evidence rather than evidence that VE-821 changes viral replication.

• Standardized Whole-Blood Stimulation in Immunometabolism

  2026-10-06

  Zhao and colleagues present a standardized whole-blood stimulation framework for examining how metabolic interventions shape cytokine responses to innate immune stimuli. The protocol’s main contribution is methodological: it supports more comparable cohort-scale immunometabolism studies while showing that metabolic pathway modulation can produce selective, rather than uniformly suppressive, immune effects.

• Mechanistic Precision Meets Translational Control

  2026-10-06

  Translational studies succeed when mechanistic claims are matched by appropriately designed controls. This thought-leadership article connects lessons from structural TRPM3 pharmacology with the interpretive role of PBS Liposomes in macrophage depletion research, while defining evidence boundaries and future opportunities.

• Standardized Whole-Blood Stimulation and Immunometabolism

  2026-10-05

  Zhao and colleagues present a standardized whole-blood framework for examining how metabolic perturbations reshape immune stimulation and cytokine production. The protocol’s main contribution is conceptual and methodological: it connects physiologically complex blood-based immune assays with controlled metabolism modulation while clarifying the limits of cytokine-based interpretation.

• ISRIB and Inflammation-Associated Memory Loss

  2026-10-05

  A source-grounded overview of how ISRIB was studied in a mouse model of inflammation-associated accelerated forgetting, what the findings suggest about ISR signaling and memory retention, and why the evidence does not yet establish clinical efficacy or direct PERK inhibition.

• Etomoxir in Immunometabolism Research

  2026-10-04

  Etomoxir is widely used as a pharmacological probe of mitochondrial fatty acid oxidation, but its interpretation requires caution because supplier-described activity also includes diacylglycerol acyltransferase inhibition and because the supplied human whole-blood study is a protocol rather than an Etomoxir-specific efficacy trial. This overview compares the available evidence, outlines conceptual applications in immunometabolism and neuroinflammation research, and defines key limitations across cell, whole-blood, and animal models.

• EZ Cap™ Cas9 mRNA: From Editing to Pharming

  2026-10-03

  EZ Cap™ Cas9 mRNA (m1Ψ) connects transient Cas9 expression with a broader evidence framework for CRISPR-Cas9 genome editing and animal pharming. This article interprets Cap1, m1Ψ, and the rabbit study without overstating what product chemistry alone can prove.

• Dual Luciferase Reporter Gene System: Practical Guide

  2026-10-02

  The Dual Luciferase Reporter Gene System pairs firefly signal strength with Renilla normalization to make promoter and transcription-factor experiments more quantitative. This guide connects the K1136 workflow with the MYC2–LBD40/42–CRL3BPM4 model of tomato defense while clearly separating validated mammalian-cell applications from future cross-domain experiments.

• HBV G1896A Drives HCC Through ER Stress and Glycolysis

  2026-10-01

  This MedComm study identifies a mechanistic link between the HBV precore G1896A mutation, PERK–ATF4 endoplasmic reticulum stress signaling, and PFKFB3-dependent aerobic glycolysis in hepatocellular carcinoma. Its rescue and in vivo experiments suggest that the ATF4–PFKFB3 axis contributes to mutation-associated tumor growth, invasion, and metastasis, while also providing a framework for studying HBV-related metabolic reprogramming.

• In Situ CAR-M Reprogramming for HCC Immunotherapy

  2026-10-01

  The reference study develops a GPC3-targeted CAR macrophage design that combines self-secreted IFN-γ with a dominant-negative SIRPα extracellular domain. Delivered as lipid nanoparticle-encapsulated mRNA, the construct reprogrammed endogenous macrophages, strengthened inflammatory activity, disrupted CD47–SIRPα signaling, and improved antitumor responses in hepatocellular carcinoma models.

8052 records 1/537 page Next 12345 下5页 Last page